Core Viewpoint - Axbio International Limited is set to go public on the Hong Kong Stock Exchange, focusing on advanced platforms for life sciences research and clinical applications, integrating IC, biotech, and AI technologies [2]. Product Development - Axbio's product pipeline includes a microarray analyzer, two EL-NGS gene sequencers, and various diagnostic reagent kits, with key products like AxiLona EL-100 and AxiLona AXP-100 [3][4]. - The AxiLona EL-100 is one of the few molecular diagnostic products in China capable of electrochemical, multi-target, rapid, low-cost, and integrated biomolecular detection, having completed clinical trials and received regulatory approval [4]. - AxiLona AXP-100 is the world's first EL-NGS gene sequencer, utilizing advanced semiconductor biochips, and AxiLona AXP-1000 is in the design phase, expected to have ten times the throughput of AXP-100 [5]. Market Opportunity - The protein detection market in China and globally is projected to grow to 94 billion yuan and 62.9 billion USD by 2033, respectively, with compound annual growth rates of 6.2% and 5.2% [4]. - Axbio aims to expand the clinical application of AxiLona EL-100 by adding protein detection capabilities to capture market opportunities [4]. Financial Overview - Axbio's valuation before the IPO is approximately 347.5 million USD, with funds raised intended for further development and commercialization of core products, as well as operational and general corporate purposes [6].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company's operating performance slightly exceeded expectations, with total revenue of 11.103 billion RMB in 2024, a year-on-year increase of 57.2%, and a net profit attributable to shareholders of 1.097 billion RMB, a year-on-year increase of 3.1% [1] - The rental income per unit has steadily increased, with the rental income per square meter reaching 92.1 RMB/month in 2024, a year-on-year increase of 15.5% [2] - The company continues to provide stable dividends, proposing a cash dividend of 2.00 RMB per 10 shares for 2024, with a payout ratio of approximately 46.0% [2] Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 11.103 billion RMB, with a year-on-year growth rate of 57.44% [4] - The net profit attributable to shareholders for 2024 was 1.097 billion RMB, with a growth rate of 3.39% [4] - For Q1 2025, total revenue was 1.581 billion RMB, a year-on-year decrease of 17.1%, and net profit was 172 million RMB, a year-on-year decrease of 16.5% [1] Rental Business - The company rented out approximately 2.699 million square meters in 2024, a year-on-year decrease of 13.9% [2] - The rental business generated revenue of 2.983 billion RMB, a year-on-year decrease of 0.87% [2] - The unit rental income has increased from 61.1 RMB/square meter/month in 2020 to 92.1 RMB/square meter/month in 2024, reflecting a compound annual growth rate (CAGR) of approximately 10.8% [2] Dividend Policy - The company plans to distribute a cash dividend of 2.00 RMB per 10 shares for 2024, totaling approximately 504 million RMB [2] - The average payout ratio from 2020 to 2024 has been around 46.3% [2] Profit Forecast and Valuation - The net profit forecasts for 2025 and 2026 have been adjusted to 1.130 billion RMB and 1.178 billion RMB, respectively [3] - The estimated earnings per share (EPS) for 2025-2027 are projected to be 0.45, 0.47, and 0.49 RMB, respectively [3] - The current stock price corresponds to a price-to-earnings (P/E) ratio of 20.4, 19.6, and 18.6 for 2025-2027 [3]

Core Company Overview - Axbio International Limited, founded in 2016, is a leader in integrated circuit biotechnology, focusing on developing next-generation electrochemical detection platforms for life sciences and diagnostics [1] - The company integrates integrated circuits, biotechnology, and artificial intelligence to create advanced foundational platforms for life science research and clinical applications [1] Key Technologies and Products - The company specializes in four key areas: integrated circuit chips, synthetic biology and chemical engineering, electrochemistry and microfluidics, and artificial intelligence, with AI being central to its innovation strategy [1] - AxiLona EL-100 is a molecular diagnostic product capable of multi-target detection, offering high sensitivity and rapid testing cycles, filling a market gap between PCR instruments and gene sequencers [3] - The AxiLona AXP-100 gene sequencer is the world's first EL-NGS platform, achieving optimal balance in accuracy, read length, cost, and speed, suitable for both clinical applications and research needs [4] Product Pipeline and Development - The product pipeline includes a microarray chip analyzer, two EL-NGS gene sequencers, and various supporting test kits [2] - The company plans to expand the clinical application of AxiLona EL-100 by adding protein detection capabilities to capture significant market opportunities [3] - AxiLona AXP-1000 is in development, featuring a high-throughput sequencing chip with ten million nanopore channels, expected to have ten times the throughput of AxiLona AXP-100 [4] Research and Development Strategy - The company has established four R&D centers in Silicon Valley, Shenzhen, Tianjin, and Wuxi, equipped with advanced facilities to support innovative research [5] - The core R&D team has nearly 100 authorized patents globally, with several more pending, showcasing a strong commitment to innovation [5] - The team comprises experts with backgrounds from prestigious institutions and organizations, ensuring a high level of expertise in semiconductor, biotechnology, and artificial intelligence [5]

Core Points - The Beijing Expert Association held its sixth first member representative conference, electing a new council with notable academicians in leadership roles [1] - The association, established in 1990, serves as a vital platform for connecting and serving experts and talents in Beijing, now boasting over a thousand members [1] - The association has optimized its member structure, enhancing representation and coverage across various fields [1] Subgroup 1: Leadership and Structure - The new leadership includes Chinese Academy of Engineering Academician Zhan Qimin as the chairman and several other prominent academicians as vice-chairmen [1][2] - The association has set up eight sub-committees led by 70 academicians, focusing on areas such as basic research, electronic information, and high-end manufacturing [2] Subgroup 2: Talent Development - Approximately one-third of the members are around 40 years old, representing young leading talents engaged in significant scientific projects and technological challenges [3] - Nearly 60% of the members come from fields like integrated circuits, artificial intelligence, and healthcare, indicating a strong focus on high-tech sectors [3] Subgroup 3: Future Initiatives - The association plans to create a core intellectual property (IP) of high-level experts in the capital, focusing on national strategic implementation and addressing critical technological challenges [4] - It aims to enhance political guidance for talents and strengthen communication with members through various educational and research activities [4] - The association will establish a talent identification mechanism and a platform for technology transfer, aiming to discover and cultivate high-potential young talents in the capital [4]

2025年4月29日，华大九天(301269.SZ)发布2025年一季报。 公司营业总收入为2.34亿元，在已披露的同业公司中排名第53，较去年同报告期营业总收入增加2086.29 万元，实现4年连续上涨，同比较去年同期上涨9.77%。归母净利润为971.39万元，在已披露的同业公司 中排名第30，较去年同报告期归母净利润增加204.85万元，同比较去年同期上涨26.72%。经营活动现金 净流入为2.40亿元，在已披露的同业公司中排名第5，较去年同报告期经营活动现金净流入增加1.77亿 元，同比较去年同期上涨281.38%。 公司最新毛利率为91.42%，在已披露的同业公司中排名第8。最新ROE为0.19%，在已披露的同业公司 中排名第45，较去年同期ROE增加0.03个百分点。 公司摊薄每股收益为0.02元，在已披露的同业公司中排名第34，较去年同报告期摊薄每股收益增加0.01 元，同比较去年同期上涨100.00%。 公司最新总资产周转率为0.04次，较去年同期总资产周转率持平，实现2年连续上涨，同比较去年同期 上涨8.23%。最新存货周转率为0.36次，较去年同期存货周转率增加0.21次，同比较去年同期上 ...

【导读】有研新材2025年第一季度净利润同比增长14698.12% 中国基金报记者 若文 4月29日，有研新材发布公告称，一季度实现营业收入18.4亿元，同比下降18.67%；净利润为6738.47万元，同比增长14698.12%。 | | | | 早征: 元 | | --- | --- | --- | --- | | | | | 本报告期比上年同 | | 项目 | 本报告期 | 上年同期 | 期增减变动幅度 | | | | | (%) | | 营业收入 | 1, 839, 801, 206. 94 | 2, 262, 259, 127. 37 | -18. 67 | | 归属于上市公司股东的净利 润 | 67, 384, 695. 82 | 455, 359. 85 | 14, 698. 12 | | 归属于上市公司股东的扣除 | 62, 937, 839. 85 | -5, 282, 238. 13 | 不适用 | | 非经常性损益的净利润 | | | | | 经营活动产生的现金流量净 | -316, 961, 207. 09 | -563, 445, 618. 82 | 不适用 | | 额 | | | ...

省领导张国智参加会见。 黄坤明代表省委、省政府欢迎何光彩一行，感谢北京大学长期以来为广东经济社会发展特别是教育科技 人才事业作出的贡献，并对近日在深圳成立的北京大学科学智能学院表示祝贺。他说，北京大学在粤布 局早，近年来省校合作日益深化，取得坚实成果。当前，广东正深入学习贯彻习近平总书记对广东系列 重要讲话和重要指示精神，围绕实现总书记赋予的使命任务，一体推进教育强省、科技创新强省、人才 强省建设，奋力在推进中国式现代化建设中走在前列。愿与北京大学进一步深化在学科建设、人才培 养、产学研协同创新等方面的合作，合力做强深圳研究生院，携手开创校地共赢发展新局面。广东产业 基础好、配套全，希望北京大学充分发挥学术、科研、人才等优势，围绕广东产业发展所需，聚焦人工 智能、集成电路、工业软件、生物医药、新能源新材料等前沿领域，强化前瞻布局，加强校企科研合 作，积极促进创新成果在粤落地转化，会同广东高校开展基础研究、平台建设，共同培养更多高层次和 拔尖创新人才，更好培育发展新质生产力。当前，我们推出的"百万英才汇南粤"系列招聘活动正在全国 各地举行，热忱欢迎北大学子抓住机遇，到广东来追逐梦想、一展身手。广东将竭诚做好服务 ...

"王国的艺术——沙特现当代艺术展"（暂定名）拟汇集约30件（组）沙特现当代艺术家的视觉艺术作 品，以全新视角引领观众探索现代沙特阿拉伯独特的文化面貌，同时揭示古老文化传统在沙特人心中留 下的深刻印记。 "国际友人与中国抗战——纪念中国人民抗日战争胜利80周年主题展"将展示在中国人民进行抗日战争的 艰苦岁月里，许多国际友人以医生、记者、工程师等身份千里迢迢来到中国，通过直接参加战斗、亲临 战场救治伤病员、深入前线报道，谱写了国际主义的英雄赞歌。 "考古中国重大项目——安徽淮南武王墩大墓展"以近年来国内最重要的考古发现之一——武王墩墓出土 文物为基础，向公众展示楚国器用制度、器物的功能与陈设、楚国外交关系，以及楚国在中华文明多元 一体中所发挥的重要作用。 在国际展览方面，"庞贝：永恒的发现"将展出那不勒斯国家考古博物馆以及庞贝和赫库兰尼姆考古公园 的部分文物，并利用各种多媒体技术让参观者清晰有效地了解难以在展览中展示的背景，揭示庞贝最新 的考古发现，为观众提供了一个在过去与现在、古代证据与最新技术之间进行交流的机会。 新京报讯（记者展圣洁）记者从国家博物馆获悉，2025年将正式推出"国家展览"品牌，通过联合国内外 ...

一、主要会计数据和财务指标 前十大流通股东累计持有： 8484.17万股，累计占流通股比： 19.2%，较上期变化： 192.64万股。 | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 国家集成电路产业投资基金股份有限公司 | 2663.36 | 6.03 | -54.30 | | 周儒欣 | 2026.39 | 4.59 | 不变 | | 周光宇 | 1284.38 | 2.91 | 不变 | | 国泰中证军工ETF | 425.78 | 0.96 | 68.80 | | 北京中域拓普投资管理有限公司-北京集成电路尖端芯片股 权投资中心(有限合伙) | 385.13 | 0.87 | 不变 | | 许丽丽 | 368.24 | 0.83 | 101.09 | | 易方达中证人工智能主题ETF | 368.00 | 0.83 | 158.62 | | 香港中央结算有限公司 | 362.71 | 0.82 | -49.17 | | 南方中证1000ETF | 326.13 | 0.74 | -32. ...

Group 1 - The Supreme People's Procuratorate (SPP) has established a specialized Intellectual Property Procuratorate to enhance judicial protection of intellectual property rights in China, marking a shift towards a more professional and comprehensive approach [1] - In the past year, the SPP received and reviewed arrests for 13,486 individuals involved in intellectual property crimes and accepted prosecutions for 33,805 individuals, with 81% of cases related to trademark infringement [2] - The SPP plans to conduct regular supervision of malicious litigation and strengthen collaboration with relevant departments to create a favorable business environment [2] Group 2 - The SPP's focus on new technologies has led to an increase in cases involving intellectual property crimes, with a notable rise in cases related to commercial secrets, which saw a 12.4% increase year-on-year [2] - The SPP aims to enhance oversight of cross-regional cases and clarify the boundaries between different types of crimes related to intellectual property [1]